Consensus molecular subtypes (CMS1-4)
The consensus molecular subtypes are four gene-expression groups of bowel cancer: immune (CMS1), canonical (CMS2), metabolic (CMS3), and mesenchymal (CMS4), with different prognoses.
Guinney et al., Nature Medicine 2015. CMS1 (14%) MSI/immune, BRAF-mutant; CMS2 (37%) WNT/MYC canonical; CMS3 (13%) KRAS, metabolic; CMS4 (23%) TGF-β, stromal, worst prognosis. Prognostic and partly predictive (CMS2 benefits most from anti-EGFR), but not yet used routinely in clinic.
Pages like this
not linked directly; found by shared links- PersonEric R. Fearon
Shares Wnt / β-catenin, Colorectal cancer.
- PersonErik Sahai
Shares Match therapy to the type of scar-forming cell in the tumour, Epithelial–mesenchymal transition & drug efflux.
- IdeaCheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress
Shares Epithelial–mesenchymal transition & drug efflux, Colorectal cancer.
- TermLGR5
Shares Wnt / β-catenin, Colorectal cancer.
- PersonKenneth W. Kinzler
Shares Wnt / β-catenin, Colorectal cancer.
- InstitutionShizuoka Cancer Center
Shares RNA sequencing & expression profiling, Colorectal cancer.
- IdeaStrip the platelet coat off travelling tumour cells in ctDNA-positive patients
Shares Epithelial–mesenchymal transition & drug efflux, Colorectal cancer.
- InstitutionMax Delbrück Center for Molecular Medicine
Shares RNA sequencing & expression profiling, Colorectal cancer.